Business context and reporting period
The supplied filing is FibroGen, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing identified as Kyntra Bio, Inc. FibroGen is a clinical-stage biopharmaceutical company developing roxadustat and pamrevlumab. Roxadustat had Chinese approval for dialysis-dependent CKD anemia; the company was preparing U.S. and European submissions with AstraZeneca and Astellas. Pamrevlumab was in clinical development.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Revenue | $23.9 million | $31.9 million; down 25% |
| Operating expenses | $72.7 million | $72.5 million; approximately flat |
| Operating loss | $48.8 million | $40.6 million |
| Net loss / diluted loss per share | $45.4 million / $0.53 | $41.4 million / $0.50 |
| Operating margin | Approximately -205% | Approximately -127% |
| Operating cash flow | $22.5 million provided | $32.0 million used |
| Cash and cash equivalents | $81.7 million | $89.3 million at Dec. 31, 2018 |
| Investments | $615.9 million | $588.0 million at Dec. 31, 2018 |
Revenue was entirely development and other revenue; there was no license revenue or product-sale revenue. The decline primarily reflected lower roxadustat co-development billings after substantial completion of Phase 3 trials. R&D expense fell 11% to $50.5 million, while SG&A rose 43% to $22.2 million, including costs to prepare for China commercialization. Net loss increased year over year.
Cash, investments and accounts receivable totaled $703.6 million at quarter-end, including $6.0 million of receivables. Operating cash flow benefited substantially from a $57.7 million reduction in accounts receivable, including collection of approximately $43.9 million related to roxadustat API delivered to Astellas in 2018; it should not be read as recurring cash generation. The company reported no conventional funded debt in the presented balance sheet, but had $58.6 million of finance-lease liabilities at March 31, 2019. Lease accounting adoption moved building arrangements onto the balance sheet. Management said available financial resources were expected to cover anticipated needs for at least 12 months, while noting the estimate could change.
Material changes, outlook, risks and unusual items
- Management expected to submit the roxadustat U.S. NDA in September or October 2019 and the European MAA thereafter; these were plans, not assurances. A China commercial launch was planned for Q3 2019, with potential non-dialysis label expansion expected in mid-2019. A Japan dialysis-anemia approval decision was expected in the second half of 2019.
- FibroGen reported preliminary roxadustat cardiovascular analyses it viewed as supportive, but emphasized that regulators would conduct their own benefit-risk assessment. FDA review, analysis methods, safety findings, labeling and possible additional studies remained important uncertainties.
- The company planned to begin Phase 3 pamrevlumab trials in IPF and locally advanced pancreatic cancer in Q2 2019. It also planned a U.S. Phase 2 roxadustat trial for chemotherapy-induced anemia in 2019. Trial outcomes and timing were uncertain.
- Key risks include clinical and regulatory failure or delay, roxadustat safety and cardiovascular assessment, dependence on AstraZeneca and Astellas, commercialization and reimbursement execution in China, competition, manufacturing and supply constraints, intellectual-property disputes, and the need for future financing. The company had not achieved profitability and expected continuing losses.
- ASC 842 adoption on January 1, 2019 resulted in recognition of lease assets and liabilities and an $8.7 million cumulative adjustment to opening accumulated deficit; it did not materially affect Q1 operating results or cash flows. Another accounting adoption reclassified $0.6 million within equity, with no income-statement or cash-flow effect.
- The filing reported no material legal proceedings, no material change in contractual obligations, and no material change in market-risk exposure. Management assessed disclosure controls as effective as of March 31, 2019.
Important facts for investors to verify
- Confirm the filing identity: the document names FibroGen, Inc. and ticker FGEN, despite the request metadata naming Kyntra Bio, Inc.
- Track actual FDA and EMA submission dates, review outcomes, and any additional analyses or trials required for roxadustat.
- Verify China launch progress, reimbursement and hospital access, manufacturing readiness, and post-approval safety-study requirements.
- Assess the recurring cash burn separately from the quarter’s receivables-driven positive operating cash flow, and monitor liquidity, lease payments and financing needs.
- Review the underlying safety data and regulatory interpretation for roxadustat, and clinical-trial progress for pamrevlumab and other programs.